Mammalian Target of Rapamycin Inhibition

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that has been increasingly recognized as key to the regulation of cell growth and proliferation. mTOR either directly or indirectly regulates translation initiation, actin organization, tRNA synthesis, ribosome biogenesis, and many other key cell maintenance functions, including protein degradation and transcription functions. Inhibition of mTOR blocks traverse of the cell cycle from the G1 to S phase. Preclinical data show inhibition of tumor growth in a number of cell lines and xenograft models. Clinical trials are ongoing. In metastatic renal cell cancer, both tumor regression and prolonged stabilization have been noted. mTOR inhibition appears to be a key pathway that may be useful in antitumor therapy. Renal cell cancer may be particularly susceptible through both the translation inhibition pathway and pathways that enhance HIF-1α gene expression, a factor believed to stimulate growth in metastatic renal cell cancer. Additional clinical trials that use agents that inhibit mTOR are ongoing.

[1]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. , 1975, The Journal of antibiotics.

[2]  P. Houghton,et al.  Studies on the mechanism of resistance to rapamycin in human cancer cells. , 1998, Molecular pharmacology.

[3]  P. Houghton,et al.  Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. , 1994, The Journal of clinical investigation.

[4]  P. Houghton,et al.  p 53 / p 21 CIP 1 Cooperate in Enforcing Rapamycin-induced G 1 Arrest and Determine the Cellular Response to Rapamycin 1 , 2001 .

[5]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. , 1975, The Journal of antibiotics.

[6]  Shile Huang,et al.  p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. , 2001, Cancer research.

[7]  Tobias Schmelzle,et al.  TOR, a Central Controller of Cell Growth , 2000, Cell.

[8]  W. Kaelin,et al.  Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Sehgal.  Sirolimus: its discovery, biological properties, and mechanism of action. , 2003, Transplantation proceedings.

[10]  S. Sehgal,et al.  Activity of rapamycin (AY-22,989) against transplanted tumors. , 1984, The Journal of antibiotics.

[11]  M. Gassmann,et al.  Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor. , 2002, Cancer research.

[12]  Hong Wu,et al.  Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Linda N. Liu,et al.  Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. , 1999, Cancer research.

[14]  J. Lawrence,et al.  Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Douros,et al.  New antitumor substances of natural origin. , 1981, Cancer treatment reviews.

[16]  Shile Huang,et al.  Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. , 2002, Current opinion in investigational drugs.

[17]  E. Sausville,et al.  Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  David J. Kwiatkowski,et al.  Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  N. Sonenberg,et al.  Eukaryotic Translation Initiation Factor 4E Regulates Expression of Cyclin D1 at Transcriptional and Post-transcriptional Levels (*) , 1995, The Journal of Biological Chemistry.

[20]  G. Mills,et al.  Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. , 1995, Cancer research.

[21]  F. Luan,et al.  Rapamycin is an effective inhibitor of human renal cancer metastasis. , 2003, Kidney international.

[22]  T. Seufferlein,et al.  Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. , 1996, Cancer research.

[23]  William R Sellers,et al.  TSC2 regulates VEGF through mTOR-dependent and -independent pathways. , 2003, Cancer cell.

[24]  A. Jaeschke,et al.  Mammalian TOR: A Homeostatic ATP Sensor , 2001, Science.

[25]  N. Sonenberg,et al.  Opposite Translational Control of GLUT1 and GLUT4 Glucose Transporter mRNAs in Response to Insulin , 1999, The Journal of Biological Chemistry.

[26]  R. Bookstein,et al.  Mutations to CCI-779 PTEN Enhanced Sensitivity of Multiple Myeloma Cells Containing Updated Version , 2002 .

[27]  M. Dimopoulos,et al.  Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. Hultsch,et al.  The effect of the immunophilin ligands rapamycin and FK506 on proliferation of mast cells and other hematopoietic cell lines. , 1992, Molecular biology of the cell.

[29]  S. Muthukkumar,et al.  RAPAMYCIN, A POTENT IMMUNOSUPPRESSIVE DRUG, CAUSES PROGRAMMED CELL DEATH IN B LYMPHOMA CELLS , 1995, Transplantation.

[30]  S. Schreiber,et al.  Chemistry and biology of the immunophilins and their immunosuppressive ligands. , 1991, Science.

[31]  D. Houchens,et al.  Human brain tumor xenografts in nude mice as a chemotherapy model. , 1983, European journal of cancer & clinical oncology.

[32]  C. Thompson,et al.  Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Hongbing Zhang,et al.  Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. , 2003, Cancer research.

[34]  P. Frost,et al.  mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. , 2001, Endocrine-related cancer.

[35]  M. Carroll,et al.  Survival of acute myeloid leukemia cells requires PI3 kinase activation. , 2003, Blood.

[36]  M. Hidalgo,et al.  The rapamycin-sensitive signal transduction pathway as a target for cancer therapy , 2000, Oncogene.

[37]  Richard B. Johnston,et al.  Chronic Granulomatous Disease: Report on a National Registry of 368 Patients , 2000, Medicine.

[38]  R. Abraham,et al.  Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. , 1995, Progress in cell cycle research.

[39]  S. Liou,et al.  Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  R. Motzer,et al.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Christine C. Hudson,et al.  Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin , 2002, Molecular and Cellular Biology.

[42]  M. Ivan,et al.  Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.

[43]  L. Shantz,et al.  Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation. , 1994, Cancer research.

[44]  S. Thiru,et al.  RAPAMYCIN FOR IMMUNOSUPPRESSION IN ORGAN ALLOGRAFTING , 1989, The Lancet.

[45]  B. Geoerger,et al.  Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. , 2001, Cancer research.

[46]  R. Perugini,et al.  FRAP-p70s6K signaling is required for pancreatic cancer cell proliferation. , 2001, The Journal of surgical research.

[47]  E. Kohn,et al.  Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[48]  Hongbing Zhang,et al.  Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. , 2003, The Journal of clinical investigation.

[49]  T. Seufferlein,et al.  Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. , 1999, Cancer research.